The American Diabetes Association (ADA) recommends the sequential initiation of GLP-1 agonist and/or SGLT2 inhibitor in four groups of patients: established atherosclerotic cardiovascular disease, heart failure or chronic kidney disease, obesity and at risk of hypoglycemia. Here, GLP1R is linked to obesity disorder.